United States Biotechnology & Medical Research

Vir Biotechnology Inc (VIR)

Track

Over the past 90 days, Vir Biotechnology Inc. has seen exclusively selling activity from insiders, totaling approximately $453,807 in value. These transactions, involving various directors and officers, occurred following the company's recent earnings report. The stock has experienced a 13.6% decline over the same period, reflecting ongoing market volatility for the healthcare firm.
Ticker: VIR Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Vir Biotechnology Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Proposed sale 29 Jun 2026
Value US$725,969.95 | Price 486.88 | Shares 68,389
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-29 2026-06-29 PrS Proposed sale
1.8
Ramasastry Saira

Former Director

Non-Executive Director
68,389
486.88
US$725,970 		68,389 486.88 US$725,970
2026-06-02 2026-06-01 PlS Planned sale
Napolitano Janet
Non-Executive Director
18,706 -1.4%
279.75
US$3,120,488 		18,706 -1.4% 279.75 US$3,120,488
2026-06-02 2026-06-01 PlS Planned sale
3.7
Sabatini Brent

SVP, Chief Accounting Officer

Officer
5,417 +6.3%
448.32
US$4,309,715 		5,417 +6.3% 448.32 US$4,309,715
2026-06-01 2026-06-01 PrS Proposed sale
3.7
Sabatini Brent

Officer

Officer
379
9.45
US$3,582 		379 9.45 US$3,582
2026-06-01 2026-06-01 PrS Proposed sale
Napolitano Janet

Director

Non-Executive Director
3,200
9.45
US$30,240 		3,200 9.45 US$30,240
2026-05-04 2026-05-01 PlS Planned sale
SATO VICKI L
Non-Executive Director
22,000 -2.0%
10.05
US$221,025 		22,000 -2.0% 10.05 US$221,025
2026-04-30 2026-04-30 PrS Proposed sale
4.0
Eisner Mark

Former Officer

Officer
88,958
10.30
US$916,267 		88,958 10.30 US$916,267
2026-04-07 2026-04-06 PlS Planned sale
3.5
De Backer Marianne

President and CEO

Executive Director
72,559 -7.1%
9.16
US$664,350 		72,559 -7.1% 9.16 US$664,350
2026-04-06 2026-04-06 PrS Proposed sale
3.5
De Backer Marianne

Officer; Director

Executive Director
72,559
9.16
US$664,343 		72,559 9.16 US$664,343
2026-04-02 2026-04-01 PlS Planned sale
SATO VICKI L
Non-Executive Director
22,000 -2.0%
9.07
US$199,617 		22,000 -2.0% 9.07 US$199,617
2026-03-24 2026-03-23 PlS Planned sale
3.7
Sabatini Brent

SVP, Chief Accounting Officer

Officer
7,711 -11.1%
9.12
US$70,324 		7,711 -11.1% 9.12 US$70,324
2026-03-23 2026-03-23 PrS Proposed sale
3.7
Sabatini Brent

Officer

Officer
7,711
9.12
US$70,324 		7,711 9.12 US$70,324
2026-03-03 2026-03-02 PlS Planned sale
SATO VICKI L
Non-Executive Director
200 -0.0%
9.98
US$1,996 		200 -0.0% 9.98 US$1,996
2026-03-03 2026-03-02 PlS Planned sale
SATO VICKI L
Non-Executive Director
21,800 -1.9%
9.50
US$207,185 		21,800 -1.9% 9.50 US$207,185
2026-03-02 2026-03-02 PrS Proposed sale
VICKI LEE SATO

Director

Non-Executive Director
88,000
9.09
US$799,920 		88,000 9.09 US$799,920
2026-02-26 2026-02-25 PlS Planned sale
4.0
Eisner Mark

EVP and Chief Medical Officer

Officer
1,889 -1.2%
9.82
US$18,550 		1,889 -1.2% 9.82 US$18,550
2026-02-26 2026-02-25 PlS Planned sale
3.7
de Verneuil Vanina

EVP, General Counsel, Corp Sec

Officer
13,700 -10.8%
9.82
US$134,534 		13,700 -10.8% 9.82 US$134,534
2026-02-25 2026-02-25 PrS Proposed sale
3.3
SVF Endurance (Cayman) Limited

Stockholder

Large shareholder
400,000
9.49
US$3,796,000 		400,000 9.49 US$3,796,000
2026-02-25 2026-02-25 PrS Proposed sale
3.7
de Verneuil Vanina

Officer

Officer
13,700
9.82
US$134,534 		13,700 9.82 US$134,534
2026-02-25 2026-02-25 PrS Proposed sale
4.0
Eisner Mark

Officer

Officer
1,889
9.82
US$18,550 		1,889 9.82 US$18,550
2026-02-26 2026-02-24 PlS Planned sale
0.5
O'Byrne Jason

EVP & Chief Financial Officer

Officer
1,634 -1.0%
9.53
US$15,576 		1,634 -1.0% 9.53 US$15,576
2026-02-26 2026-02-24 PlS Planned sale
SATO VICKI L
Non-Executive Director
200 -0.0%
10.26
US$2,052 		200 -0.0% 10.26 US$2,052
2026-02-26 2026-02-24 PlS Planned sale
SATO VICKI L
Non-Executive Director
42,177 -3.6%
9.75
US$411,314 		42,177 -3.6% 9.75 US$411,314
2026-02-26 2026-02-24 PlS Planned sale
3.7
Sabatini Brent

SVP, Chief Accounting Officer

Officer
1,430 -2.0%
9.53
US$13,632 		1,430 -2.0% 9.53 US$13,632
2026-02-26 2026-02-24 PlS Planned sale
4.0
Eisner Mark

EVP and Chief Medical Officer

Officer
1,616 -1.0%
9.53
US$15,405 		1,616 -1.0% 9.53 US$15,405
2026-02-26 2026-02-24 PlS Planned sale
3.7
de Verneuil Vanina

EVP, General Counsel, Corp Sec

Officer
3,117 -2.4%
9.53
US$29,713 		3,117 -2.4% 9.53 US$29,713
2026-02-26 2026-02-24 PlS Planned sale
3.5
De Backer Marianne

Chief Executive Officer

Executive Director
14,762 -1.4%
9.53
US$140,720 		14,762 -1.4% 9.53 US$140,720
2026-02-24 2026-02-24 PrS Proposed sale
4.0
Eisner Mark

Officer

Officer
1,616
9.53
US$15,405 		1,616 9.53 US$15,405
2026-02-24 2026-02-24 PrS Proposed sale
3.5
De Backer Marianne

Officer; Director

Executive Director
14,762
9.53
US$140,720 		14,762 9.53 US$140,720
2026-02-24 2026-02-24 PrS Proposed sale
0.5
O'Byrne Jason

Officer

Officer
1,634
9.53
US$15,576 		1,634 9.53 US$15,576
2026-02-24 2026-02-24 PrS Proposed sale
3.7
Sabatini Brent

Officer

Officer
1,430
9.53
US$13,632 		1,430 9.53 US$13,632
2026-02-24 2026-02-24 PrS Proposed sale
3.7
de Verneuil Vanina

Officer

Officer
3,117
9.53
US$29,713 		3,117 9.53 US$29,713
2026-02-24 2026-02-24 PrS Proposed sale
VICKI LEE SATO

Director

Non-Executive Director
20,377
7.43
US$151,401 		20,377 7.43 US$151,401
2026-02-24 2026-02-23 PlS Planned sale
3.7
Sabatini Brent

SVP, Chief Accounting Officer

Officer
1,829 -2.5%
7.45
US$13,631 		1,829 -2.5% 7.45 US$13,631
2026-02-24 2026-02-23 PlS Planned sale
0.5
O'Byrne Jason

EVP & Chief Financial Officer

Officer
2,089 -1.3%
7.45
US$15,569 		2,089 -1.3% 7.45 US$15,569
2026-02-24 2026-02-23 PlS Planned sale
4.0
Eisner Mark

EVP and Chief Medical Officer

Officer
2,089 -1.3%
7.45
US$15,569 		2,089 -1.3% 7.45 US$15,569
2026-02-24 2026-02-23 PlS Planned sale
3.7
de Verneuil Vanina

EVP, General Counsel, Corp Sec

Officer
4,445 -3.3%
7.45
US$33,128 		4,445 -3.3% 7.45 US$33,128
2026-02-24 2026-02-23 PlS Planned sale
3.5
De Backer Marianne

Chief Executive Officer

Executive Director
19,039 -1.8%
7.45
US$141,894 		19,039 -1.8% 7.45 US$141,894
2026-02-23 2026-02-23 PrS Proposed sale
0.5
O'Byrne Jason

Officer

Officer
2,089
7.45
US$15,569 		2,089 7.45 US$15,569
2026-02-23 2026-02-23 PrS Proposed sale
4.0
Eisner Mark

Officer

Officer
2,089
7.45
US$15,569 		2,089 7.45 US$15,569
2026-02-23 2026-02-23 PrS Proposed sale
3.5
De Backer Marianne

Officer; Director

Executive Director
19,039
7.45
US$141,894 		19,039 7.45 US$141,894
2026-02-23 2026-02-23 PrS Proposed sale
3.7
de Verneuil Vanina

Officer

Officer
4,445
7.45
US$33,128 		4,445 7.45 US$33,128
2026-02-23 2026-02-23 PrS Proposed sale
3.7
Sabatini Brent

Officer

Officer
1,829
7.45
US$13,631 		1,829 7.45 US$13,631
2026-02-18 2026-02-13 PlS Planned sale
3.7
Sabatini Brent

SVP, Chief Accounting Officer

Officer
1,530 -3.1%
7.79
US$11,919 		1,530 -3.1% 7.79 US$11,919
2026-02-13 2026-02-13 PrS Proposed sale
3.7
Sabatini Brent

Officer

Officer
1,530
7.79
US$11,918 		1,530 7.79 US$11,918
2026-02-03 2026-02-02 PlS Planned sale
SATO VICKI L
Non-Executive Director
22,000 -1.9%
7.71
US$169,671 		22,000 -1.9% 7.71 US$169,671
2026-01-14 2026-01-14 PrS Proposed sale
3.3
SVF Endurance (Cayman) Limited

Stockholder

Large shareholder
1,251,303
6.82
US$8,533,886 		1,251,303 6.82 US$8,533,886
2026-01-05 2026-01-02 PlS Planned sale
SATO VICKI L
Non-Executive Director
22,000 -1.9%
5.93
US$130,383 		22,000 -1.9% 5.93 US$130,383
2026-01-02 2026-01-02 PrS Proposed sale
VICKI LEE SATO

Director

Non-Executive Director
66,000
6.03
US$397,980 		66,000 6.03 US$397,980
2025-12-03 2025-12-01 PlS Planned sale
3.3
SVF Endurance (Cayman) Ltd
Large shareholder
191,854 -1.4%
5.98
US$1,147,786 		191,854 -1.4% 5.98 US$1,147,786
2025-12-02 2025-12-01 PlS Planned sale
SATO VICKI L
Non-Executive Director
22,000 -1.8%
6.00
US$132,070 		22,000 -1.8% 6.00 US$132,070
2025-12-01 2025-11-28 PlS Planned sale
3.3
SVF Endurance (Cayman) Ltd
Large shareholder
61,493 -0.4%
6.44
US$396,015 		61,493 -0.4% 6.44 US$396,015
2025-12-01 2025-11-26 PlS Planned sale
3.3
SVF Endurance (Cayman) Ltd
Large shareholder
127,938 -0.9%
6.39
US$817,652 		127,938 -0.9% 6.39 US$817,652
2025-11-26 2025-11-25 PlS Planned sale
3.3
SVF Endurance (Cayman) Ltd
Large shareholder
235,971 -1.6%
6.38
US$1,505,495 		235,971 -1.6% 6.38 US$1,505,495
2025-11-25 2025-11-25 PrS Proposed sale
3.3
SVF Endurance (Cayman) Limited

10% Stockholder

Large shareholder
1,251,303
6.44
US$8,058,391 		1,251,303 6.44 US$8,058,391
2025-11-26 2025-11-24 PlS Planned sale
3.3
SVF Endurance (Cayman) Ltd
Large shareholder
227,803 -1.6%
6.15
US$1,400,783 		227,803 -1.6% 6.15 US$1,400,783
2025-11-18 2025-11-17 S Sale
0.5
O'Byrne Jason

EVP & Chief Financial Officer

Officer
6,799 -5.8%
5.56
US$37,782 		6,799 -5.8% 5.56 US$37,782
2025-11-17 2025-11-17 PrS Proposed sale
0.5
O'Byrne Jason

Officer

Officer
6,799
5.56
US$37,781 		6,799 5.56 US$37,781
2025-11-07 2025-11-05 PlS Planned sale
3.7
de Verneuil Vanina

EVP, General Counsel, Corp Sec

Officer
2,385 -3.0%
5.16
US$12,307 		2,385 -3.0% 5.16 US$12,307
2025-11-05 2025-11-05 PrS Proposed sale
3.7
de Verneuil Vanina

Officer

Officer
2,385
5.16
US$12,307 		2,385 5.16 US$12,307
2025-11-04 2025-11-03 S Sale
3.7
de Verneuil Vanina

EVP and General Counsel

Officer
1,365 -1.7%
5.86
US$8,003 		1,365 -1.7% 5.86 US$8,003
2025-11-04 2025-11-03 PlS Planned sale
SATO VICKI L
Non-Executive Director
22,000 -1.8%
5.64
US$124,047 		22,000 -1.8% 5.64 US$124,047
2025-11-03 2025-11-03 PrS Proposed sale
3.7
de Verneuil Vanina

Officer

Officer
1,365
5.86
US$8,003 		1,365 5.86 US$8,003
2025-10-30 2025-10-29 PlS Planned sale
3.3
SVF Endurance (Cayman) Ltd
Large shareholder
100 -0.0%
6.49
US$649 		100 -0.0% 6.49 US$649
2025-10-30 2025-10-28 PlS Planned sale
3.3
SVF Endurance (Cayman) Ltd
Large shareholder
24,453 -0.2%
6.50
US$159,006 		24,453 -0.2% 6.50 US$159,006
2025-10-28 2025-10-27 PlS Planned sale
3.3
SVF Endurance (Cayman) Ltd
Large shareholder
66,403 -0.5%
6.05
US$401,585 		66,403 -0.5% 6.05 US$401,585
2025-10-28 2025-10-24 PlS Planned sale
3.3
SVF Endurance (Cayman) Ltd
Large shareholder
46,696 -0.3%
5.96
US$278,285 		46,696 -0.3% 5.96 US$278,285
2025-10-24 2025-10-23 PlS Planned sale
3.3
SVF Endurance (Cayman) Ltd
Large shareholder
154,383 -1.0%
5.99
US$924,723 		154,383 -1.0% 5.99 US$924,723
2025-10-24 2025-10-22 PlS Planned sale
3.3
SVF Endurance (Cayman) Ltd
Large shareholder
144,266 -1.0%
6.15
US$887,654 		144,266 -1.0% 6.15 US$887,654
2025-10-22 2025-10-21 PlS Planned sale
3.3
SVF Endurance (Cayman) Ltd
Large shareholder
109,675 -0.7%
6.30
US$690,974 		109,675 -0.7% 6.30 US$690,974
2025-10-21 2025-10-21 PrS Proposed sale
3.3
SVF Endurance (Cayman) Limited

10% Stockholder

Large shareholder
834,202
6.27
US$5,230,447 		834,202 6.27 US$5,230,447
2025-10-22 2025-10-20 PlS Planned sale
3.3
SVF Endurance (Cayman) Ltd
Large shareholder
220,535 -1.4%
6.20
US$1,367,273 		220,535 -1.4% 6.20 US$1,367,273
2025-10-17 2025-10-16 PlS Planned sale
3.3
SVF Endurance (Cayman) Ltd
Large shareholder
12,844 -0.1%
6.10
US$78,366 		12,844 -0.1% 6.10 US$78,366
2025-10-17 2025-10-15 PlS Planned sale
3.3
SVF Endurance (Cayman) Ltd
Large shareholder
16,671 -0.1%
6.07
US$101,196 		16,671 -0.1% 6.07 US$101,196
2025-10-14 2025-10-10 PlS Planned sale
3.3
SVF Endurance (Cayman) Ltd
Large shareholder
2,300 -0.0%
6.08
US$13,973 		2,300 -0.0% 6.08 US$13,973
Explore more

More insider trading research around Vir Biotechnology Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America